teladoc he_老虎社区_美港股上老虎

Rashamon96
2021-10-26

teladoc health is one of the services used during pandemic.

3 Stocks Cathie Wood Is Buying That You Might Want to Consider Too

How successful of an investor is Cathie Wood? Consider that over the last five years, the two best-p

3 Stocks Cathie Wood Is Buying That You Might Want to Consider Too

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":852124259,"tweetId":"852124259","gmtCreate":1635254951280,"gmtModify":1635255951959,"author":{"id":3586937187491404,"idStr":"3586937187491404","authorId":3586937187491404,"authorIdStr":"3586937187491404","name":"Rashamon96","avatar":"https://static.tigerbbs.com/c800b60e9a6b67f29f6a9438054010ae","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>teladoc health is one of the&nbsp;services used during pandemic.&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>teladoc health is one of the&nbsp;services used during pandemic.&nbsp;</p></body></html>","text":"teladoc health is one of the services used during pandemic.","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/852124259","repostId":2178087594,"repostType":4,"repost":{"id":"2178087594","pubTimestamp":1635250757,"share":"https://www.laohu8.com/m/news/2178087594?lang=&edition=full","pubTime":"2021-10-26 20:19","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That You Might Want to Consider Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2178087594","media":"Motley Fool","summary":"How successful of an investor is Cathie Wood? Consider that over the last five years, the two best-p","content":"<p>How successful of an investor is Cathie Wood? Consider that over the last five years, the two best-performing non-leveraged exchange-traded funds (ETFs) were her <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b> and <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b>. And her <b>ARK Genomic Revolution ETF</b> came in at No. 5.</p>\n<p>The kinds of stocks that Wood likes aren't for everyone. They're often high-risk, potentially high-reward plays that are suitable only for aggressive investors. If you don't mind taking on considerable risk, here are three stocks Wood is buying that you might want to consider too.</p>\n<h2>1. Beam Therapeutics</h2>\n<p>Both the ARK Innovation ETF and ARK Genomic Revolution ETF have scooped up more shares of&nbsp;<b>Beam Therapeutics</b> (NASDAQ:BEAM) in October. The biotech stock is only one spot away from jumping into the top 10 holdings for the ARKG ETF.</p>\n<p>Beam specialized in base editing. It's a type of gene editing that enables pinpoint rewriting of a specific letter in the genome. And Beam's approach could prove to be more important over the long run than other types of gene editing.</p>\n<p>The company doesn't have any candidates in clinical testing yet. That could change relatively soon, though, with Beam on track to submit an Investigational New Drug (IND) application within the next couple of months for BEAM-101 in treating rare blood disorders beta-thalassemia and sickle cell disease.</p>\n<p>Beam's market cap stands above $6 billion. That's a quite lofty valuation for a preclinical-stage biotech. However, if the company's base editing works in one indication, it could potentially be applied in many other indications. Wood obviously thinks the chances that will happen are worth placing a major bet on Beam Therapeutics.</p>\n<h2>2. CRISPR Therapeutics</h2>\n<p>Beam Therapeutics isn't the only gene-editing stock that Wood likes these days. Her ARK Innovation ETF and ARK Genomic Revolution ETF have also added to their positions in <b>CRISPR Therapeutics</b> (NASDAQ:CRSP) in recent weeks.</p>\n<p>CRISPR Therapeutics could become the first biotech focused on CRISPR gene editing to have a shot at getting a product on the market. The company and its partner <b>Vertex Pharmaceuticals</b>&nbsp;hope to file for regulatory approvals of CTX001 in 2023. CTX001 is a CRISPR gene-editing therapy targeting beta-thalassemia and sickle cell disease.</p>\n<p>Some investors were disappointed with the durability of response in CRISPR Therapeutics' phase 1 data for its off-the-shelf chimeric antigen receptor T cell (CAR-T) therapy CTX110. However, the day after those results were announced, Wood chose to buy more shares of the stock at a discount.</p>\n<p>CRISPR Therapeutics' market cap of over $7 billion might be hard to swallow for cautious investors. But with the prospects of potentially launching its first product in 2024 and a still-promising pipeline of gene-editing therapies, the company could become a big player in healthcare over the long run.</p>\n<h2>3. Teladoc Health</h2>\n<p>There's no question that&nbsp;<b>Teladoc Health</b> (NYSE:TDOC) remains one of Wood's favorite stocks. So far in October, three of her ARK ETFs have bought additional Teladoc shares. Teladoc ranks as the top holding of the ARK Genomic Revolution ETF. It's the second-largest position in the ARK Innovation ETF. The telehealth stock is even in the top 10 for the <b><a href=\"https://laohu8.com/S/ARKF\">ARK Fintech Innovation ETF</a></b>.</p>\n<p>Some investors have soured on Teladoc this year due to concerns about slowing membership growth. However, the company continues to perform well overall. Visits have risen. Revenue per member per month is up. Utilization rates are climbing.</p>\n<p>On the other hand, Wall Street hasn't given up on the stock. Analysts think that Teladoc could soar close to 40% over the next 12 months. This optimism about Teladoc from both Wood and Wall Street centers on the company's long-term prospects.</p>\n<p>The virtual care market remains only in its early stages. Teladoc is the clear leader in the market. It also continues to launch new products and services that provide further competitive advantages. Of these three stocks being bought by Wood recently, Teladoc is the least risky while still offering strong growth prospects.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That You Might Want to Consider Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That You Might Want to Consider Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-26 20:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/26/3-stocks-cathie-wood-is-buying-that-you-might-want/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>How successful of an investor is Cathie Wood? Consider that over the last five years, the two best-performing non-leveraged exchange-traded funds (ETFs) were her ARK Next Generation Internet ETF and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/26/3-stocks-cathie-wood-is-buying-that-you-might-want/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRSP":"CRISPR Therapeutics AG","TDOC":"Teladoc Health Inc.","BEAM":"Beam Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/10/26/3-stocks-cathie-wood-is-buying-that-you-might-want/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178087594","content_text":"How successful of an investor is Cathie Wood? Consider that over the last five years, the two best-performing non-leveraged exchange-traded funds (ETFs) were her ARK Next Generation Internet ETF and ARK Innovation ETF. And her ARK Genomic Revolution ETF came in at No. 5.\nThe kinds of stocks that Wood likes aren't for everyone. They're often high-risk, potentially high-reward plays that are suitable only for aggressive investors. If you don't mind taking on considerable risk, here are three stocks Wood is buying that you might want to consider too.\n1. Beam Therapeutics\nBoth the ARK Innovation ETF and ARK Genomic Revolution ETF have scooped up more shares of Beam Therapeutics (NASDAQ:BEAM) in October. The biotech stock is only one spot away from jumping into the top 10 holdings for the ARKG ETF.\nBeam specialized in base editing. It's a type of gene editing that enables pinpoint rewriting of a specific letter in the genome. And Beam's approach could prove to be more important over the long run than other types of gene editing.\nThe company doesn't have any candidates in clinical testing yet. That could change relatively soon, though, with Beam on track to submit an Investigational New Drug (IND) application within the next couple of months for BEAM-101 in treating rare blood disorders beta-thalassemia and sickle cell disease.\nBeam's market cap stands above $6 billion. That's a quite lofty valuation for a preclinical-stage biotech. However, if the company's base editing works in one indication, it could potentially be applied in many other indications. Wood obviously thinks the chances that will happen are worth placing a major bet on Beam Therapeutics.\n2. CRISPR Therapeutics\nBeam Therapeutics isn't the only gene-editing stock that Wood likes these days. Her ARK Innovation ETF and ARK Genomic Revolution ETF have also added to their positions in CRISPR Therapeutics (NASDAQ:CRSP) in recent weeks.\nCRISPR Therapeutics could become the first biotech focused on CRISPR gene editing to have a shot at getting a product on the market. The company and its partner Vertex Pharmaceuticals hope to file for regulatory approvals of CTX001 in 2023. CTX001 is a CRISPR gene-editing therapy targeting beta-thalassemia and sickle cell disease.\nSome investors were disappointed with the durability of response in CRISPR Therapeutics' phase 1 data for its off-the-shelf chimeric antigen receptor T cell (CAR-T) therapy CTX110. However, the day after those results were announced, Wood chose to buy more shares of the stock at a discount.\nCRISPR Therapeutics' market cap of over $7 billion might be hard to swallow for cautious investors. But with the prospects of potentially launching its first product in 2024 and a still-promising pipeline of gene-editing therapies, the company could become a big player in healthcare over the long run.\n3. Teladoc Health\nThere's no question that Teladoc Health (NYSE:TDOC) remains one of Wood's favorite stocks. So far in October, three of her ARK ETFs have bought additional Teladoc shares. Teladoc ranks as the top holding of the ARK Genomic Revolution ETF. It's the second-largest position in the ARK Innovation ETF. The telehealth stock is even in the top 10 for the ARK Fintech Innovation ETF.\nSome investors have soured on Teladoc this year due to concerns about slowing membership growth. However, the company continues to perform well overall. Visits have risen. Revenue per member per month is up. Utilization rates are climbing.\nOn the other hand, Wall Street hasn't given up on the stock. Analysts think that Teladoc could soar close to 40% over the next 12 months. This optimism about Teladoc from both Wood and Wall Street centers on the company's long-term prospects.\nThe virtual care market remains only in its early stages. Teladoc is the clear leader in the market. It also continues to launch new products and services that provide further competitive advantages. Of these three stocks being bought by Wood recently, Teladoc is the least risky while still offering strong growth prospects.","news_type":1},"isVote":1,"tweetType":1,"viewCount":607,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["AONE.U"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":50,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}